50675-18-8

Basic information

• Product Name: Tetrahydropyran-4-carbaldehyde
• Synonyms: 4-FORMYLTETRAHYDROPYRAN;TETRAHYDRO-2H-PYRAN-4-CARBALDEHYDE;TETRAHYDRO-PYRAN-4-CARBALDEHYDE;TETRAHYDROPYRANYL-4-CARBOXALDEHYDE;Tetrahydro-2H-pyran-4-carboxaldehyde;Tetrahydropyran-4-carboxaldehyde;Tetrahydropyran-4-carboxaldehyde 95%;TETRAHYDRO-PYRAN-4-CARBALDEHYD
• CAS NO: 50675-18-8
• Molecular Formula: C₆H₁₀O₂
• Molecular Weight: 114.14
• Product Categories: Aldehydes;blocks;Heterocycles;Building Blocks;Pyran
• Mol File: 50675-18-8.mol
• Article Data: 33

Chemical Properties

• Boiling Point: 176.921 °C at 760 mmHg
• Flash Point: >23℃
• Appearance: /
• Density: 1.097 g/cm³
• Vapor Pressure: 1.067mmHg at 25°C
• Refractive Index: 1.513
• Storage Temp.: Keep Cold
• CAS DataBase Reference: Tetrahydropyran-4-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: Tetrahydropyran-4-carbaldehyde(50675-18-8)
• EPA Substance Registry System: Tetrahydropyran-4-carbaldehyde(50675-18-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36-20/21/22
• Safety Statements: 26-36/37-24/25
• RIDADR: 1993
• Hazardous Substances Data: 50675-18-8(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

Uses

4-Formyltetrahydropyran is used in preparation of the heterocyclic compounds and their medical applications.

InChI:InChI=1/C6H10O2/c7-5-6-1-3-8-4-2-6/h5-6H,1-4H2

Upstream product

• 185-72-8 1,6-dioxa-spiro[2.5]octane 
• 5435-44-9 (E)-3-Ureido-but-2-enoic acid ethyl ester 
• 6192-52-5 p-toluenesulfonic acid monohydrate 
• 144-55-8 sodium hydrogencarbonate 
• 101765-10-0 tetrahydro-4-(methoxymethylene)-2H-pyran 
• 50-00-0 formaldehyd 
• 96835-17-5 ethyl tetrahydro-2H-pyran-4-carboxylate 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 14774-37-9 (tetrahydro-2H-pyran-4-yl)methanol 
• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 4295-99-2 tetrahydro-2H-pyran-4-carbonitrile 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 2081-44-9 Tetrahydro-pyran-4-ol 

Downstream Products

• 99228-16-7 tetrahydropyran-4-yl-acrylic acid ethyl ester 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 582299-19-2 2-hydroxy-1-phenyl-2-(3,4,5,6-tetrahydro-2H-pyran-4-yl) ethan-1-one 
• 582299-04-5 2-oxo-2-phenyl-1-(3,4,5,6-tetrahydro-2H-pyran-4-yl)ethyl 4-methylbenzene-1-sulfonate 
• 685886-66-2 N-(cyclopropylmethyl)-7-iodo-2-(methylthio)-N-[(tetrahydro-2H-pyran-4-yl)methyl]pyrazolo[1,5-a]pyridin-3-amine 
• 685886-48-0 7-bromo-N-(cyclopropylmethyl)-2-ethyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]pyrazolo[1,5-a]pyridin-3-amine 
• 685886-64-0 7-bromo-N-(cyclopropylmethyl)-2-methoxy-N-((tetrahydropyran-3-yl)methyl)pyrazolo[1,5-a]pyridin-3-amine 
• 1159280-52-0 9-oxaspiro[5.5]undec-4-en-3-one 
• 875798-35-9 (5-{2-[(tetrahydro-pyran-4-ylmethyl)-amino]-ethyl}-thiazol-2-yl)-carbamic acid tert-butyl ester 
• 1035267-55-0 C₁₆H₂₀BrFO₂S₂ 
• 1408865-76-8 C₁₂H₂₀N₂O 
• 1221504-10-4 (tetrahydro-2H-pyran-4-ylmethyl)hydrazine trifluoroacetic acid 

Relevant articles and documents

SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR

Provided is a sulfonyl-substituted bicyclic compound (A) which acts as a RORγ inhibitor, said compound has good RORγ inhibitory activity and is expected to be used for treating diseases mediated by a RORγ receptor in mammals.

Axial-to-Central Chirality Transfer for Construction of Quaternary Stereocenters via Dearomatization of BINOLs

All-carbon quaternary stereocenters are versatile building blocks, and their asymmetric construction has attracted much attention. Herein, we disclose an axial-to-central chirality transfer strategy for the synthesis of chiral quaternary stereocenters via dearomatization of (S)-BINOLs. The reaction proceeded smoothly with a wide range of propargyl carbonates to afford chiral spiro-compounds in high yields with excellent enantioselectivities. In addition, the strategy was extended to kinetic resolution of rac-BINOLs albeit with moderate s value.

METHODS OF MAKING AND USING PDE9 INHIBITORS

The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.